Q4 2024 Earnings Call Transcript February 7, 2025 Iterum Therapeutics plc beats earnings expectations. Reported EPS is $-0.12 ...

Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from ...

On January 7, 2025, the U.S. Food and Drug Administration (“FDA” or “Agency”) released a long-awaited guidance titled, “Communications From Firms ...

AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...

The FDA approved 16 psychiatric drugs over the last decade, most of which shared similar mechanisms of action with previously ...

AbbVie (NYSE:ABBV) said it has received FDA approval for the intravenous antibiotic treatment Emblaveo, which was co-developed with Pfizer (NYSE:PFE). The FDA approved Emblaveo, a combination of ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

Groundbreaking personalized kidney cancer vaccines show promise in early clinical trials, triggering strong immune responses ...

On January 14, 2025, the Biden administration’s U.S. Environmental Protection Agency (EPA) posted a last-minute “interim” decision in the ...

Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Learn more about ...